Targeted drug shows promise for rare vulvar cancer

NCT ID NCT07672782

Not yet recruiting Disease control Sponsor: GOG Foundation Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests a drug called tisotumab vedotin in people with advanced squamous cell carcinoma of the vulva that has returned or spread. The drug is an antibody-drug conjugate designed to seek out and destroy cancer cells. The study aims to see how many participants' tumors shrink or disappear, and monitors side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tisotumab vedotin
What this could lead to: If successful, this could offer a new treatment option for people with advanced vulvar cancer that has returned or spread.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drug can cause side effects like nerve damage or infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC VULVAR CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis Recurrence squamous cell carcinoma vulva cancer vulvar carcinoma vulvar squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR METASTATIC VULVAR CANCER SQUAMOUS CELL CARCINOMA VULVA VULVAR CARCINOMA

Contacts and locations

Locations

Atrium Health Levine Cancer Center

Charlotte, North Carolina, 28204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.